Current Problems in Cancer

Current Problems in Cancer is a bimonthly oncology journal from Elsevier that began in 1976 as a series of single-topic monographs and now publishes practice-oriented clinical and translational cancer research, with a 2025 Journal Impact Factor of 2.4 and a CiteScore of 4.7.《癌症当前问题》是 Elsevier 出版的双月刊肿瘤学期刊，1976 年以每期一题的专著式丛书起步，如今刊发面向临床实践的转化与临床肿瘤研究，2025 年期刊影响因子为 2.4，CiteScore 为 4.7。

Scope

• The stated mission is to promote and disseminate innovative, transformative and impactful data on patient-oriented cancer research, with clinical care rather than laboratory mechanism as the organising centre.该刊的公开宗旨是传播以患者为导向的肿瘤研究数据，强调创新性、变革性与实际影响力，落脚点在临床诊疗而非实验室机制。
• Editorial selection applies a usefulness test, because a study should either alter practice or map a new direction in translational and clinical cancer research, and papers that do neither fall outside the remit.选题遵循实用性标准，研究要么改变临床实践，要么为转化与临床肿瘤研究指出新方向，两者皆无的稿件不在收录范围。
• Novel therapeutic approaches form the first pillar, covering dose-finding and early-phase trials, new agents and combinations, and treatment sequences that shift outcomes for a defined population.新型治疗途径是第一根支柱，涵盖剂量探索与早期临床试验、新药及联合方案，以及能改变特定人群结局的治疗排序。
• A second strand is earlier and sharper diagnosis, taking in screening policy, detection assays, staging pathways and the evidence that decides whether a new test improves outcomes instead of merely moving the point of diagnosis.第二条主线是更早、更准的诊断，涵盖筛查政策、检测方法、分期路径，以及判断新检测能否改善结局而不仅仅提前给出诊断的证据。
• Cancer clinical trials sit at the centre of the remit, from first-in-human studies through pragmatic and registry-based designs, with attention to endpoints, accrual and the reporting standards that let a reader judge whether a result travels.肿瘤临床试验居于核心位置，从人体首试到实用性设计与登记研究设计皆在其列，关注终点设定、入组进度，以及让读者判断结果可否外推的报告规范。
• Supportive care belongs in the same frame as tumour control, so symptom management, palliative integration, survivorship and quality-of-life endpoints are treated as clinical outcomes in their own right.支持治疗与肿瘤控制同处一个框架，症状管理、姑息治疗整合、生存者照护与生活质量终点都被视为独立的临床结局。
• Translational correlates are welcome when they answer a clinical question, such as biomarker selection, pharmacodynamic read-outs or imaging measures that change how a patient is managed.能回答临床问题的转化研究同样受欢迎，例如生物标志物筛选、药效学读出，或改变患者管理方式的影像学指标。
• The aims state plainly that pre-clinical studies are discouraged, so bench work is expected to sit inside a patient-oriented argument instead of standing alone as mechanism.该刊在收录范围说明中明确不鼓励临床前研究，实验室工作需要嵌入以患者为导向的论证之中，不能单独作为机制探讨成篇。
• Alongside standard articles the journal keeps its founding habit of the themed collection, assembling a curated set of reviews that examines one tumour type or one problem from several angles.在常规论文之外，该刊保留了创刊时的专题结集传统，用一组经过挑选的综述从多个角度审视某一种肿瘤或某一个难题。
• Review articles carry much of the teaching load, and they are edited for clinic use, with clear figures, explicit evidence grading and a short statement of what should change in the next treatment plan.综述承担了大部分教学功能，编辑时以临床可用为准，要求图表清晰、证据分级明确，并用简短篇幅说明下一份治疗方案应当改动什么。
• Case reports are steered to the open access companion title (Current Problems in Cancer: Case Reports), and any case report sent to the flagship is considered for publication in either journal.病例报告被引导至开放获取的姊妹刊（Current Problems in Cancer: Case Reports），投给主刊的病例报告会在两刊之间择一考虑。
• The reader the journal has in mind is a practising oncologist, a surgical or radiation colleague, or a trainee who needs a defensible summary of a field that moves faster than the textbooks.该刊设定的读者是执业肿瘤科医生、外科或放疗科同道，以及需要一份可靠领域概述的受训医师，教材的更新速度已落后于证据产出。
• Authorship is multidisciplinary by design and draws on medical oncology, surgery, radiation oncology, pathology and imaging, which matches the way treatment decisions are actually made in tumour boards.作者队伍按多学科方式组织，覆盖内科肿瘤、外科、放疗、病理与影像，与肿瘤多学科会诊中治疗决策的真实形成过程相吻合。

History

• Volume 1, number 1 appeared in July 1976 from Year Book Medical Publishers in Chicago, a house then known for the annual yearbook compendia that distilled the literature for practising physicians.第 1 卷第 1 期于 1976 年 7 月由芝加哥的 Year Book Medical Publishers 出版，这家出版社当时以每年一册的年鉴式文献汇编闻名，服务对象是执业医师。
• The founding format was a stand-alone monograph, with one issue given to one problem, written by an invited authority and issued as a small hardback, which is where the wording of the title comes from.创刊形态是独立专著，一期只谈一个问题，由受邀专家执笔，以小开本精装发行，刊名正由此而来。
• Six issues a year were the pattern from the opening volumes, and apart from occasional combined numbers that rhythm has held for five decades.从最初几卷起就是每年 6 期，除偶尔合并期号外，这一节奏保持了五十年。
• The imprint moved from Chicago to St. Louis, where Mosby took over publication, a change recorded in the National Library of Medicine catalogue entry for the title.出版地随后由芝加哥迁至圣路易斯，改由 Mosby 出版，这一变动记录在美国国家医学图书馆的刊目条目中。
• Mosby's health sciences list joined Elsevier in the early 2000s, and the journal now appears under Elsevier copyright on ScienceDirect while Mosby survives as the imprint on the record.Mosby 的医学出版资产在 2000 年代初并入 Elsevier，该刊如今以 Elsevier 版权在 ScienceDirect 发布，Mosby 则作为刊目上的出版印记保留。
• Volume numbering has stayed at one volume a year, so volume 47 closed in 2023 with six issues to the volume, which is the arithmetic behind the bimonthly label.卷号长期保持每年一卷，第 47 卷于 2023 年收尾，每卷 6 期，双月刊的说法由此而来。
• Indexing came early, as MEDLINE lists the journal from volume 1, number 1 of July 1976, PubMed gives the same start, and the title also sits in Index Medicus.收录时间很早，MEDLINE 自 1976 年 7 月的第 1 卷第 1 期起收录，PubMed 的起始时间相同，Index Medicus 亦在列。
• The content model shifted by degrees, with original research articles added to the monographic core, and by the 2020s the weight had moved toward practice-changing studies and away from tutorial reviews.内容模式逐步改动，原创研究论文被加入专著式核心，到 2020 年代，实践改变型研究的分量已超过教程式综述。
• The current aims go further than the founding brief by discouraging pre-clinical submissions outright, which narrows the journal to work that already carries a patient-facing question.现行收录范围比创刊时的设想更进一步，直接写明不鼓励临床前投稿，把刊物收窄到已经带有患者相关问题的研究。
• A companion title, Current Problems in Cancer: Case Reports, took over descriptive case material under an open access model, leaving the flagship free to concentrate on studies with comparative evidence.姊妹刊（Current Problems in Cancer: Case Reports）以开放获取模式承接描述性病例材料，主刊得以集中刊发带对照证据的研究。
• From 2024 the deposits in Crossref show a turn to article-based publication, as volumes advance through 48 to 53 inside a single year and carry no issue numbers.自 2024 年起，Crossref 的登记显示该刊转为按篇出版，一年之内卷号从 48 推进到 53，且不再标注期号。
• Open access is hybrid, so authors may publish on the subscription track at no charge or pay an article publishing charge for gold open access, and 21.48% of the 2025 output was gold open access.开放获取为混合模式，作者可以免费按订阅方式发表，也可以支付论文处理费走金色开放获取，2025 年有 21.48% 的文章属于金色开放获取。
• The 2025 Journal Impact Factor is 2.4 and the five-year figure 2.6, while the Journal Citation Indicator of 0.55 places the title 214th of 333 journals in Oncology, in the third quartile.2025 年期刊影响因子为 2.4，五年影响因子为 2.6，期刊引文指标为 0.55，在肿瘤学 333 种期刊中列第 214 位，处于第三四分位。
• Impact has been flat rather than climbing, at 2.367 in 2022, 2.5 in 2023, 2.3 in 2024 and 2.4 in 2025, set against total citations of 1,472 and a cited half-life of 5.4 years.影响因子近年走平，2022 年为 2.367，2023 年为 2.5，2024 年为 2.3，2025 年为 2.4，总被引 1472 次，引用半衰期为 5.4 年。

Editors

• Editorial responsibility is shared by two editors-in-chief, Shivaani Kummar and P. Lara Jr., an arrangement that pairs a developmental-therapeutics programme with a large public academic health system.编辑责任由两位主编分担，即（Shivaani Kummar）与（P. Lara Jr.），这一安排把早期药物开发项目与大型公立学术医疗系统配在一起。
• Kummar heads the Division of Hematology and Medical Oncology at Oregon Health & Science University in Portland and is known for first-in-human and phase I work in precision oncology.（Shivaani Kummar）在波特兰的俄勒冈健康与科学大学主持血液与肿瘤内科，以精准肿瘤学领域的人体首试与 I 期研究著称。
• Lara works from UC Davis Health in Sacramento, where he has led cooperative-group trials and built the cancer centre's clinical research portfolio.（P. Lara Jr.）在萨克拉门托的加州大学戴维斯分校健康中心工作，主持过合作组试验，并搭建了该肿瘤中心的临床研究体系。
• Ten associate editors support them, drawn from the United States, India, Ireland and Korea, and their affiliations run from the Jawaharlal Institute in Puducherry to Asan Medical Center in Seoul.十位副编辑协助工作，分别来自美国、印度、爱尔兰与韩国，单位从本地治里的贾瓦哈拉尔研究生医学教育与研究所一直到首尔的峨山医疗中心。
• The associate group includes Andrew Birkeland and Lorenzo Nardo at UC Davis, Ursa Brown-Glaberman at New Mexico, Prasanth Ganesan at JIPMER, Apar Kishor Ganti at Nebraska, Gregory Heestand at Stanford and Naoko Takebe at Rochester.副编辑团队包括加州大学戴维斯分校的（Andrew Birkeland）与（Lorenzo Nardo）、新墨西哥大学的（Ursa Brown-Glaberman）、JIPMER 的（Prasanth Ganesan）、内布拉斯加大学的（Apar Kishor Ganti）、斯坦福大学的（Gregory Heestand）以及罗切斯特大学的（Naoko Takebe）。
• Three more associates widen the map, namely Lalit Kumar at Artemis Hospitals in Gurugram, Geraldine O'Sullivan Coyne at Mater Misericordiae University Hospital in Dublin, and Sook Ryun Park at Asan Medical Center.另外三位副编辑扩展了版图，分别是古尔冈阿耳忒弥斯医院的（Lalit Kumar）、都柏林仁慈圣母大学医院的（Geraldine O'Sullivan Coyne），以及峨山医疗中心的（Sook Ryun Park）。
• Nam Bui holds the case-report section, the editorial seat that handles manuscripts in that format before they are routed.（Nam Bui）担任病例报告栏目的分区编辑，负责处理这一体裁的稿件并决定其去向。
• Rajat Thawani, also at Oregon Health & Science University, is the commissions editor and plans the themed review collections that the journal still runs.同样任职于俄勒冈健康与科学大学的（Rajat Thawani）担任组稿编辑，负责规划该刊仍在出版的专题综述结集。
• The board is compact, since Elsevier lists 31 editors and board members in 8 countries, with the United States contributing 19, India 5 and the United Kingdom 2.编委会规模不大，Elsevier 列出的编辑与编委共 31 人，分布在 8 个国家，其中美国 19 人、印度 5 人、英国 2 人。
• The publisher's board survey, answered by 59.4% of members, reports 74% men, 21% women and 5% who prefer not to disclose, and those figures are published beside the masthead.出版方的编委调查回收率为 59.4%，结果显示男性占 74%、女性占 21%、5% 选择不披露，这些数字与编委名单一并公布。
• Manuscripts enter through Elsevier's online submission system and are assessed by the editors first, so a technically sound study with no bearing on how patients are treated can be declined before any referee sees it.稿件经 Elsevier 的在线投稿系统进入，先由编辑评估，技术合格却与患者处置无关的研究，可能在送外审之前就被退掉。
• Review is single anonymized, and the guide for authors states that a suitable submission is normally sent to at least two independent reviewers, with the editors taking the final decision on acceptance.评审采用单匿名方式，作者指南写明合适的稿件通常送交至少两位独立审稿人，录用与否由编辑作出最终决定。
• The masthead separates three functions that many journals merge, as the two editors-in-chief set direction, associate editors handle papers and the commissions editor plans forthcoming themes.编委名单把许多期刊混在一起的三项职能分开，两位主编定方向，副编辑处理稿件，组稿编辑规划后续专题。